Translation News and Research

RSS

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

A new treatment platform developed by researchers at The University of Texas MD Anderson Cancer Center was able to deliver messenger RNA (mRNA) of the full-length DMD gene into preclinical models of Duchenne muscular dystrophy, successfully restoring the production of an important muscle protein, dystrophin, and dramatically improving muscle strength, endurance and function in vivo.

11 Jun 2026

American Society for Nutrition and The Obesity Society launch strategic collaboration to advance health

In a significant step forward for advancing science to support public health, the American Society for Nutrition (ASN) and The Obesity Society (TOS) are proud to announce a new strategic alliance that unites two leading scientific organizations under a shared vision: advancing health through the best in nutrition and obesity research and practice.

9 Jun 2026

Patient organizations strengthen support for people with rheumatic diseases

Rheumatic and musculoskeletal diseases (RMD) are chronic, often lifelong conditions. EULAR - The European Alliance of Associations for Rheumatology - works with the network of national organizations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence among decision makers - creating powerful alliances that make a real difference to lives.

7 Jun 2026

New findings highlight risks and therapeutic targets in systemic sclerosis

Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs.

7 Jun 2026

Study reveals distinct sociodemographic risk factors in rare myopathies

Idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions with substantial morbidity.

5 Jun 2026

Study shows early disease activity predicts systemic sclerosis progression

In an oral abstract presentation on Thursday 4th June, results were shared from a longitudinal observational analysis of the EUSTAR database – a large multicenter online database that prospectively follows more than 25,000 patients across over 200 international centers.

4 Jun 2026

Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies

EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.

4 Jun 2026

New manufacturing platform produces targeted mixtures of beneficial gut bacteria

Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for patients with recurrent Clostridioides difficile (C. difficile) infection.

3 Jun 2026

CAR-T cell therapy shows promise for treating rheumatoid arthritis

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

3 Jun 2026

Continuing gout therapy during remission lowers future flare risk

The European Alliance of Associations for Rheumatology - held its 2026 annual Congress in London, where gout was high on the agenda.

3 Jun 2026

New PET imaging platform improves osteosarcoma surgery precision

A new end-to-end PET imaging approach for osteosarcoma can rapidly and reliably distinguish tumor tissue from normal tissue and accurately assess surgical margins in real time.

2 Jun 2026

Novel theranostic approach targets aggressive neuroendocrine prostate cancer

A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy.

2 Jun 2026

Introducing Evosep Proteomics to standardize and scale proteomics for research and drug development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

New blood test tracks real time gene expression inside living brain tissue

Cell function is determined by how DNA is expressed into proteins. That process includes two main steps - transcription, when messenger RNA (mRNA) makes copies of active genes, and translation, when mRNA guides protein assembly.

2 Jun 2026

New PET radiotracer provides noninvasive diagnosis for primary aldosteronism

A new first-in-human study has validated a PET radiotracer that can effectively image overactive adrenal glands, offering an alternative to the highly invasive procedure currently utilized to diagnose primary aldosteronism.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).

1 Jun 2026

Study reveals right ventricle better tolerates oxygen loss during cardiac arrest

A study led by scientists at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) provides new insights into ventricular fibrillation (VF), the most dangerous type of cardiac arrhythmia.

29 May 2026

AI-powered atlas maps immune structures across multiple cancer types

In a new study published today in Science, researchers from The University of Texas MD Anderson Cancer Center developed a spatial atlas of specialized immune structures, called tertiary lymphoid structures (TLSs), across multiple cancer types.

28 May 2026

How the right diet could support the gut bacteria that matter most

This review examines how gut keystone bacteria shape microbiome stability, disease risk, and responses to diet. It highlights why better identification methods, experimental validation, and precision diet-probiotic strategies are needed to restore gut homeostasis.

26 May 2026